Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMM (https://www.myeloma.org/videos/results-iberdomide-combination-dex-daratumumab-or-bortezomib-patients-rrmm)
What is the purpose of this study?
To find out the safety and efficacy of iberdomide with dexamethasone and daratumumab (IberDd) or bortezomib and dexamethasone (IberVd).
In this video:
Dr. Neils van de Donk discussed the safety and efficacy of the two triplet regimens in patients with relapsed/refractory multiple myeloma – 27 patients were assigned to IberDd and 23 were assigned to IberVd.
Conclusion:
Triplet combinations consisting of iberdomide with dexamethasone and daratumumab or bortezomib and dexamethasone demonstrated favorable tolerability profiles and promising clinical activity in patients with heavily pretreated multiple myeloma.
ASH 2020: Abstract 724 (https://ash.confex.com/ash/2020/webprogram/Paper137743.html)
Neils van de Donk, MD
Niels van de Donk, MD, PhD, is a Hematologist at the VU University Medical Center, Amsterdam, Netherlands.